Chen et al. (2015) demonstrated decreased serum tetranectin levels in patients with stable coronary artery disease [16], while McDonald et al. (2020) reported reduced circulating tetranectin levels in heart failure patients and highlighted its potential as a diagnostic biomarker [17]. Here, CLEC3B is linked to coronary artery disorder.